Medical Laboratory Techniques Department, Al-maarif University College, Anbar, Iraq; Biotechnology department, College of Applied Science, Fallujah University, Anbar, Iraq.
Department of Pathological Analyses, Faculty of Science, University of Kufa, Najaf, Iraq.
Pathol Res Pract. 2024 Feb;254:155119. doi: 10.1016/j.prp.2024.155119. Epub 2024 Jan 11.
According to estimates, cancer will be the leading cause of death globally in 2022, accounting for 9.6 million deaths. At present, the three main therapeutic modalities utilized to treat cancer are radiation therapy, chemotherapy, and surgery. However, during treatment, tumor cells resistant to chemotherapy may arise. Drug resistance remains a major oppose since it often leads to therapeutic failure. Furthermore, the term "acquired drug resistance" describes the situation where tumor cells already display drug resistance before undergoing chemotherapy. However, little is still known about the basic mechanisms underlying chemotherapy-induced drug resistance. The development of new technologies and bioinformatics has led to the discovery of additional genes associated with drug resistance. Long noncoding RNA plasmacytoma variant translocation 1 (PVT1) has been linked to an increased risk of cancer, according to a growing body of research. Apart from biological functions associated with cell division, development, pluripotency, and cell cycle, lncRNA PVT1 contributes significantly to the regulation of various aspects of genome function, such as transcription, splicing, and epigenetics. The article will address the mechanism by which lncRNA PVT1 influences drug resistance in cancer cells.
据估计，癌症将成为 2022 年全球主要的死亡原因，导致 960 万人死亡。目前，用于治疗癌症的三种主要治疗方法是放射疗法、化疗和手术。然而，在治疗过程中，可能会出现对化疗有抗药性的肿瘤细胞。耐药性仍然是一个主要的障碍，因为它经常导致治疗失败。此外，“获得性耐药性”一词描述的是肿瘤细胞在接受化疗之前就已经具有耐药性的情况。然而，人们对化疗诱导的耐药性的基本机制仍然知之甚少。新技术和生物信息学的发展发现了与耐药性相关的更多基因。越来越多的研究表明，浆细胞瘤变异易位 1（PVT1）与癌症风险增加有关。除了与细胞分裂、发育、多能性和细胞周期相关的生物学功能外，lncRNA PVT1 还显著调节基因组功能的各个方面，如转录、剪接和表观遗传学。本文将探讨 lncRNA PVT1 影响癌细胞耐药性的机制。
